Bottom line
Switching GLP-1s is straightforward — most transitions do not require a washout period because the drugs share the same core mechanism. The exact protocol depends on which two drugs you are moving between and whether the switch is for efficacy, tolerability, cost, or insurance reasons.
Your prescriber should guide any switch. This article helps you understand the process, know what to expect, and ask the right questions.
This guide covers the five most common switches in 2026:
- Wegovy to Zepbound (efficacy)
- Ozempic to Wegovy (indication alignment)
- Zepbound to Wegovy (CV indication, insurance)
- Injection to Wegovy Pill (preference, needle aversion)
- Brand to Compounded or back (cost, quality)
Common reasons people switch
Before getting into the specific protocols, it helps to understand why patients switch in the first place. The most common reasons:
- Plateau. Weight loss has stalled for 8+ weeks at maximum tolerated dose. This is the number one reason for switching from semaglutide to tirzepatide.
- Side effects. GI symptoms (nausea, vomiting, constipation) that do not resolve after adequate titration time. Some patients tolerate one molecule much better than another.
- Cost or insurance changes. Formulary changes, job changes, or coverage denials that make the current drug unaffordable. This is increasingly common as insurers shift preferred formularies.
- Supply issues. While largely resolved by 2026, intermittent supply disruptions still push some patients to switch.
- Clinical indication shift. A patient on Ozempic for diabetes who now qualifies for a weight management indication, or a patient wanting Wegovy's cardiovascular evidence from the SELECT trial.
- Route of administration preference. Patients tired of injections wanting the Wegovy Pill, or patients struggling with the pill's fasting protocol wanting to switch to injection.
When NOT to switch
Before committing to a switch, make sure you have given the current drug a fair trial. Common situations where patience is the better move:
- You have not reached the target dose yet. Most of the weight loss from GLP-1s happens at the higher doses. Switching at Wegovy 1.0 mg or Zepbound 5 mg because weight loss seems slow is premature — you may respond well at the full dose.
- You are within the first 4 weeks at a new dose step. Side effects and efficacy both take time to stabilize after each dose increase. Wait at least 4 weeks before judging.
- You have missed doses recently. Inconsistent dosing can mimic a plateau. Get back on schedule for 4-6 weeks before considering a switch.
- The plateau is less than 8 weeks. Short plateaus are normal, especially between dose escalations or during periods of lifestyle change.
If you are unsure, consult a prescriber before making a change.
Wegovy to Zepbound {#wegovy-to-zepbound}
The most common switch. Typical reasons: plateau below goal, higher efficacy sought (SURMOUNT-5 showed tirzepatide produced 47% more weight loss than semaglutide), insurance preference change, or better GI tolerability of tirzepatide at similar efficacy.
Dose equivalency context: There is no exact dose-for-dose equivalence between semaglutide and tirzepatide because they are different molecules with different receptor profiles. The convention is to restart tirzepatide titration from the beginning regardless of your semaglutide dose, though some prescribers start at 5 mg if the patient was on full-dose Wegovy.
Typical protocol: 1. Take last Wegovy dose on schedule. 2. Wait 1 week (skip the next Wegovy injection). 3. Start Zepbound 2.5 mg. 4. Titrate normally: 2.5 to 5 mg at 4 weeks, then by 2.5 mg every 4 weeks as tolerated to target (10 or 15 mg).
No washout longer than 1 week is typically needed because both drugs are GLP-1-class and steady-state concentrations clear within a few half-lives.
Some prescribers skip the washout and go directly from Wegovy's injection day to Zepbound 2.5 mg one week later — effectively replacing the next Wegovy dose with Zepbound.
What to expect: mild GI recurrence at 2.5 mg is normal as your body adjusts to the dual GIP/GLP-1 mechanism versus GLP-1 alone. Often resolves by week 2-3. Most patients see renewed weight loss within 4-8 weeks of reaching a therapeutic tirzepatide dose.
Timeline: expect 12-16 weeks from your first Zepbound dose to reaching your target maintenance dose. Weight loss response typically becomes clear within 4-8 weeks of reaching that dose.
Ozempic to Wegovy {#ozempic-to-wegovy}
The second most common switch. Typical reason: on Ozempic off-label for weight loss and want the full 2.4 mg dose with on-label insurance coverage.
Typical protocol:
- On Ozempic 0.5 mg: switch to Wegovy 0.5 mg same week.
- On Ozempic 1.0 mg: switch to Wegovy 1.0 mg same week.
- On Ozempic 2.0 mg: switch to Wegovy 1.7 mg for 4 weeks, then Wegovy 2.4 mg.
Same molecule at corresponding doses — no washout, no titration restart. The higher doses (Wegovy 2.4 mg does not have an Ozempic equivalent) require a brief step-up.
Insurance note: this switch often requires a new prior authorization. Your prescriber will need to document the obesity indication separately from the diabetes indication, even though the molecule is identical. Some insurers will not cover both at the same time, so make sure the Ozempic PA is discontinued before the Wegovy PA is submitted if they are through the same plan.
What to expect: minimal change in side effects at matched doses. Patients moving from Ozempic 2.0 mg to Wegovy 2.4 mg sometimes see slightly more nausea at the higher dose.
Zepbound to Wegovy {#zepbound-to-wegovy}
Less common but real reasons: established cardiovascular disease wanting Wegovy's SELECT evidence, insurance carrier changed preferred formulary, unmanageable GI side effects at Zepbound doses.
Typical protocol: 1. Last Zepbound dose on schedule. 2. Wait 1 week. 3. Start Wegovy at 1.7 mg (if coming from Zepbound 7.5-10 mg) or at 1.0 mg (if coming from Zepbound 2.5-5 mg). 4. Escalate to 2.4 mg after 4 weeks.
What to expect: expect modestly less weight loss over time. Stopping tirzepatide often reveals how much of your response came from the GIP receptor activity semaglutide does not cover. Some patients experience a few pounds of regain during the transition period — this is normal and usually stabilizes.
Injection to Wegovy Pill {#injection-to-pill}
Reasons: needle aversion, travel frequency, preference for oral.
Typical protocol from Wegovy injection:
- From Wegovy 1.7 mg: Wegovy Pill 14 mg daily for 4 weeks, then 25 mg daily.
- From Wegovy 2.4 mg: Wegovy Pill 25 mg daily (direct, though some prescribers do a 14 mg transition week).
Typical protocol from Zepbound injection: there is no direct tirzepatide-to-pill path, so the transition is molecular. Usually:
- Zepbound 5-7.5 mg: Wegovy Pill 14 mg for 4 weeks, then 25 mg.
- Zepbound 10-15 mg: Wegovy Pill 14 mg for 4 weeks, then 25 mg, with the expectation that efficacy will be lower than at Zepbound maintenance.
Switching from pill to injection is also possible and sometimes necessary. Patients who struggle with the strict fasting requirements of oral semaglutide (30 minutes before food or other medications, taken with minimal water) may find the weekly injection simpler to adhere to. The reverse protocol mirrors the forward one — match the dose as closely as possible and adjust over 4 weeks.
What to expect: expect some loss of efficacy when moving off tirzepatide. The pill's strict fasting protocol is a real adherence challenge — read the Wegovy Pill page before switching.
Brand to Compounded or back {#brand-to-compounded}
With identical-molecule tirzepatide and semaglutide compounding largely ended after FDA shortage-list removal in 2024-2025, most "compounded" alternatives in 2026 are non-identical analogs of uncertain equivalence.
Typical reasons to switch TO compounded:
- Insurance dropped brand coverage
- Cannot afford brand cash price
- Privacy / off-grid preference
Typical reasons to switch BACK to brand:
- Insurance now covers brand
- Concerns about compounded analog quality
- Clinical team advises standardization
Protocol: at equivalent doses, compounded to brand switches are immediate with no washout. Brand to compounded analog switches may produce different tolerability since the molecules are not identical.
What to tell your prescriber: be specific about what you were taking — the exact compound, the dose, the pharmacy. Your prescriber needs this information to set the right starting dose on the brand drug and to document your medication history accurately.
If you are considering compounded, read insurance coverage in 2026 first — you may have coverage options you have not exhausted.
Managing side effects during a switch
The transition period between drugs is when side effects are most likely to flare. Practical steps that help:
- Eat smaller, more frequent meals during the first 2 weeks on the new drug.
- Stay well hydrated. GI side effects are worse when you are dehydrated.
- Avoid high-fat meals in the first 1-2 weeks. Fat slows gastric emptying further and worsens nausea.
- Keep anti-nausea basics on hand — ginger, peppermint tea, bland crackers. Talk to your prescriber about ondansetron if nausea is severe.
- Do not skip meals entirely. Eating nothing makes nausea worse for most patients on GLP-1s.
Insurance and prior authorization implications
Almost every switch requires a new prior authorization (PA). Plan for this:
- Start the PA process 2-4 weeks before you plan to switch. Do not wait until your current supply runs out.
- Your prescriber's office handles the PA submission, but you should follow up with your insurer directly if you have not heard back within 7-10 business days.
- Switching drug classes (e.g., semaglutide to tirzepatide) often requires step therapy documentation — proof that you tried the insurer's preferred drug first. Make sure your medical records reflect this.
- Switching within the same molecule (Ozempic to Wegovy, Mounjaro to Zepbound) may still require a separate PA because the indication changes.
- If your PA is denied, see the insurance denial appeal guide for next steps.
What every switch has in common
- No washout longer than 1 week for same-class switches.
- Dose matching by pharmacokinetic equivalence, not by brand label.
- Brief GI side effect recurrence at the new drug's first dose.
- Insurance PA may need to be re-run for the new drug.
- Pen/supplies change — do not pre-order the next month until you are sure the switch is happening.
Most GLP-1 switches work. The ones that fail are usually switches back to old-generation drugs (e.g., Wegovy to Saxenda), where the efficacy drop makes the change not worth it.
See the Sherpa Matcher if you are not sure which drug fits your current situation better.